Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib dosing regimens in metastatic colorectal cancer
NCT01975077Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2012
- Primary completion
- Apr 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib in colorectal cancer (CRC) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Safety and Tolerability. Started Dec 2012; status: completed.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01975077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01975077.